

Ref. No: 2550
Date: 5th May
Subject: Biologics Rheumatology

REQUEST AND RESPONSE

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] 62
- Adalimumab [Humira] 41
- Adalimumab Biosimilars 422
- Apremilast [Otezla] <5
- Apremilast [Generic] <5
- Baricitinib [Olmiant] 11
- Bimekizumab [Bimzelx] 7
- Certolizumab [Cimzia] 36
- Etanercept [Enbrel] 35
- Etanercept Biosimilars 242
- Filgotinib [Jyseleca] 19
- Golimumab [Simponi] 41
- Golimumab Biosimilar 0
- Guselkumab [Tremfya] 11
- Infliximab [Remicade] 0
- Infliximab Biosimilars 29
- Ixekizumab [Taltz] 11
- Risankizumab [Skyrizi] <5
- Rituximab [MabThera] 0
- Rituximab Biosimilars 42
- Sarilumab [Kevzara] <5
- Secukinumab [Cosentyx] 93
- Tocilizumab [Ro Actemra] 13
- Tocilizumab Biosimilars 45
- Tofacitinib [Xeljanz] 26
- Upadacitinib [Rinvoq] 41
- Ustekinumab [Stelara] 0
- Ustekinumab Biosimilar 15

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis (PsA) ONLY in the last 3 months with the following drugs:

- Abatacept [Orencia] 0
- Adalimumab [Humira] 0
- Adalimumab Biosimilars 33
- Apremilast [Otezla] <5
- Apremilast [Generic] 0
- Bimekizumab [Bimzelx] 6
- Certolizumab [Cimzia] <5
- Etanercept [Enbrel] <5
- Etanercept Biosimilars 22
- Golimumab [Simponi] <5
- Golimumab Biosimilar 0
- Guselkumab [Tremfya] <5
- Infliximab [Remicade] 0
- Infliximab Biosimilars <5
- Ixekizumab [Taltz] <5
- Risankizumab [Skyrizi] 0
- Secukinumab [Cosentyx] 27
- Tofacitinib [Xeljanz] <5
- Upadacitinib [Rinvoq] 0
- Ustekinumab [Stelara] 0
- Ustekinumab Biosimilar <5